Rosuvastatin blood pressure
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest rosuvastatin therapy generally reduces blood pressure and improves cardiovascular health in patients with hypertension and dyslipidemia.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
The Impact of Rosuvastatin on Blood Pressure: A Comprehensive Review
Introduction to Rosuvastatin and Blood Pressure
Rosuvastatin, a statin primarily used for lowering cholesterol, has been investigated for its potential effects on blood pressure (BP). This article synthesizes findings from multiple studies to provide a clear understanding of how rosuvastatin influences BP in various patient populations.
Antihypertensive Effects of Rosuvastatin in Hypertensive Patients
Systolic and Diastolic Blood Pressure Reduction
A meta-analysis of randomized controlled trials (RCTs) involving patients with hypertension and dyslipidemia revealed that rosuvastatin significantly reduces diastolic blood pressure (DBP) by an average of 2.12 mmHg compared to control groups. Although the reduction in systolic blood pressure (SBP) was not statistically significant, there was a trend towards lower SBP with rosuvastatin treatment.
Blood Pressure Variability and Endothelial Function
In studies involving genetically dyslipidemic mice, rosuvastatin was shown to improve blood pressure variability (BPV) and heart rate variability (HRV) by enhancing nitric oxide (NO) synthase function and reducing caveolin-1 expression, an inhibitor of endothelial NO synthase. These changes suggest that rosuvastatin can positively affect cardiovascular function beyond its lipid-lowering properties.
Combination Therapies Involving Rosuvastatin
Fixed-Dose Combinations with Antihypertensive Agents
Several studies have explored the efficacy of fixed-dose combination (FDC) therapies that include rosuvastatin and antihypertensive agents. For instance, a study on the combination of telmisartan and rosuvastatin demonstrated significant reductions in both SBP and DBP compared to monotherapy with either drug alone. This combination also showed superior efficacy in achieving target BP and LDL-C levels.
Similarly, a combination of rosuvastatin and amlodipine was found to be more effective in reducing BP and LDL-C levels than either drug alone, with a significant percentage of patients achieving their BP and lipid targets.
Rosuvastatin and Candesartan
Another study evaluated the combination of candesartan and rosuvastatin, showing significant reductions in both SBP and DBP, as well as improvements in lipid profiles. This combination therapy was well-tolerated and provided a convenient treatment option for patients with both hypertension and hypercholesterolemia.
Mechanisms of Blood Pressure Reduction
PPARgamma and SOD1 Upregulation
Research on obese dyslipidemic mice indicated that rosuvastatin upregulates PPARgamma and SOD1 in the endothelium, which may contribute to its BP-lowering effects. This upregulation was associated with improved BP homeostasis, independent of changes in body weight or plasma cholesterol levels.
Effects on Angiotensin II and Endothelial Function
In patients with ischemic stroke-complicated hypertension, rosuvastatin was shown to improve endothelial function and reduce angiotensin II levels, contributing to better BP control and cerebral blood flow.
Long-Term Cardiovascular Benefits
The HOPE-3 study, which followed participants for 8.7 years, found that rosuvastatin significantly reduced major adverse cardiovascular events (MACE) by 21%. This long-term benefit was observed even after the cessation of the trial medications, indicating a lasting positive impact on cardiovascular health.
Conclusion
Rosuvastatin has demonstrated modest but significant reductions in DBP and a trend towards lower SBP in hypertensive patients. Its benefits extend beyond lipid-lowering, improving BPV, endothelial function, and long-term cardiovascular outcomes. Combination therapies involving rosuvastatin and antihypertensive agents offer enhanced efficacy in managing both hypertension and dyslipidemia, providing a comprehensive approach to cardiovascular risk reduction.
Sources and full results
Most relevant research papers on this topic
